Eli Lilly And Co vs Quanta Services Inc — how do they compare? Eli Lilly And Co trades at $1,220.99 (market cap $1.08T), while Quanta Services Inc trades at $679 (market cap $100.82B). The key difference: Eli Lilly And Co is far larger — about 10.7× Quanta Services Inc's market cap, and Eli Lilly And Co pays the higher dividend (0.57%). Which is the better fit depends on your goals.
| LLY | PWR | |
|---|---|---|
Market Cap | $1.08T | $100.82B |
Sector | Health | Industrials |
52-Week High | $1.24K | $785.24 |
52-Week Low | $639.43 | $372.50 |
Enterprise Value | $1.13T | $106.91B |
Dividend Yield | 0.57% | 0.07% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
PWR trades at $677.91, up 2.58% today, with strong technical momentum above key support at $664. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating expectations by 28%, revenue growth accelerating to $28.48B in 2025, and a record backlog supporting raised 2026 guidance. Analyst sentiment remains overwhelmingly positive with 72% buy ratings and a $809.75 consensus target.
PWR offers compelling growth exposure to infrastructure demand, particularly in power and data centers, but faces valuation concerns with a P/E of 76.7x. Near-term risks include execution on large projects and macroeconomic sensitivity, while institutional accumulation and strong cash flow generation support the bullish thesis.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →